Mavacamten Has Potential to Adjust Life Years, But Isn't as Cost Effective as Expected
August 19th 2021At a placeholder price of $75,000 per year for mavacamten used along with standard first-line treatment for symptomatic obstructive hypertrophic cardiomyopathy was above the threshold of $150,000 per QALY.
Read More
FDA Updates: An Interchangeable Biosimilar for Insulin Leads the Week
July 31st 2021Approval of the first interchangeable biosimilar; new indications for Keytruda, Botox, and Nucala; Shingrix label's expanded to a new patient population; and Ardelyx’s Complete Response Letter round out this week's FDA news.
Read More
FDA Updates: Merck’s Pneumococcal Vaccine Leads the Week
July 24th 2021New vaccine for pneumococcal disease, an sNDA approved based on real-world data, a new therapy for skin and muscle disease, Keytruda combination receives full approval in endometrial cancer, a new diabetes therapy is approved, and another JAK inhibitor misses PDUFA date round out this week’s FDA news.
Read More